Replimune

Nov 12, 2024

•

Sep 30, 2024

Replimune Q2 2025 Earnings Report

Reported financial results for the fiscal second quarter and provided a corporate update.

Key Takeaways

Replimune Group, Inc. announced financial results for the fiscal second quarter ended September 30, 2024. The company believes that existing cash, cash equivalents and short-term investments, as of September 30, 2024 will enable the Company to fund operations into the second half of 2026.

Rapid progress towards BLA submission for RP1.

IGNYTE data presented at major medical meetings, well-received by the oncology community.

Focus on ongoing preparation for commercialization, including building field teams and developing market access teams.

Cash, cash equivalents and short-term investments will fund operations into the second half of 2026.